{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:18:56Z","timestamp":1761311936992,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stichting Vriendenfonds Albert Schweitzer ziekenhuis"},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["SLP2015-7769"],"award-info":[{"award-number":["SLP2015-7769"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In patients with a biopsy-proven ductal carcinoma in situ (DCIS), axillary staging is frequently performed, but in hindsight often turns out to be superfluous. The aim of this observational study was to develop a prediction model for risk of lymph node metastasis in patients with a biopsy-proven DCIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were received from the Dutch Pathology Databank and the Netherlands Cancer Registry. The population-based cohort consisted of all biopsy-proven DCIS patients diagnosed in the Netherlands in 2011 and 2012. The prediction model was evaluated with the area under the curve (AUC) of the receiver operating characteristic, and a calibration plot and a decision curve analysis and was validated in a Dutch cohort of patients diagnosed in the period 2016\u20132019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2892 biopsy-proven DCIS patients, 127 had metastasis (4.4%). Risk factors were younger age (OR = 0.97, 95% CI 0.95\u20130.99), DCIS not detected by screening (OR = 1.55, 95% CI 1.01\u20132.38), suspected invasive component at biopsy (OR = 1.86, 95% CI 1.01\u20133.41), palpable tumour (OR = 2.06, 95% CI 1.34\u20133.18), BI-RADS score 5 (OR = 2.41, 95% CI 1.53\u20133.78), intermediate-grade DCIS (OR = 3.01, 95% CI 1.27\u20137.15) and high-grade DCIS (OR = 3.20, 95% CI 1.36\u20137.54). For 24% (<jats:italic>n<\/jats:italic> = 708) of the patients, the predicted risk of lymph node metastasis was above 5%. Based on the decision curve analysis, the model had a net benefit for a predicted risk below 25%. The AUC was 0.745. Of the 2269 patients in the validation cohort, 53 (2.2%) had metastasis and the AUC was 0.741.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This DCIS-met model can support clinical decisions on axillary staging in patients with biopsy-proven DCIS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12900-7","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T20:02:11Z","timestamp":1670702531000},"page":"2142-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-3717","authenticated-orcid":false,"given":"Claudia J. C.","family":"Meurs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9187-244X","authenticated-orcid":false,"given":"Joost","family":"van Rosmalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-4962","authenticated-orcid":false,"given":"Marian B. E.","family":"Menke-Pluijmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-824X","authenticated-orcid":false,"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-920X","authenticated-orcid":false,"given":"Pieter J.","family":"Westenend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"issue":"13","key":"12900_CR1","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1245\/s10434-015-4547-7","volume":"22","author":"AM Francis","year":"2015","unstructured":"Francis AM, Haugen CE, Grimes LM, et al. Is sentinel lymph node dissection warranted for patients with a diagnosis of ductal carcinoma in situ? Ann Surg Oncol. 2015;22(13):4270\u20139. https:\/\/doi.org\/10.1245\/s10434-015-4547-7.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"12900_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.breast.2005.08.007","volume":"14","author":"P Veronesi","year":"2005","unstructured":"Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast. 2005;14(6):520\u20132. https:\/\/doi.org\/10.1016\/j.breast.2005.08.007.","journal-title":"Breast"},{"issue":"3","key":"12900_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.breast.2015.01.004","volume":"24","author":"S Prendeville","year":"2015","unstructured":"Prendeville S, Ryan C, Feeley L, et al. Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast. 2015;24(3):197\u2013200. https:\/\/doi.org\/10.1016\/j.breast.2015.01.004.","journal-title":"Breast"},{"issue":"3","key":"12900_CR4","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.clbc.2016.10.002","volume":"17","author":"C Heymans","year":"2017","unstructured":"Heymans C, van Bastelaar J, Visschers RGJ, Vissers YLJ. Sentinel node procedure obsolete in lumpectomy for ductal carcinoma in situ. Clin Breast Cancer. 2017;17(3):e87\u201393. https:\/\/doi.org\/10.1016\/j.clbc.2016.10.002.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"12900_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41416-018-0276-6","volume":"119","author":"CJC Meurs","year":"2018","unstructured":"Meurs CJC, van Rosmalen J, Menke-Pluijmers MBE, et al. A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers. Br J Cancer. 2018;119(9):1155\u201362. https:\/\/doi.org\/10.1038\/s41416-018-0276-6.","journal-title":"Br J Cancer"},{"key":"12900_CR6","unstructured":"National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management (Guideline NG101). https:\/\/www.nice.org.uk\/guidance\/ng101\/chapter\/Recommendations#surgery-to-the-breast. Published 2018. Accessed March 15, 2022"},{"key":"12900_CR7","unstructured":"Nationaal Borstkanker Overleg Nederland (NABON). Treatment guideline DCIS, the Netherlands. Online. https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/dcis.html. Published 2017. Accessed March 15, 2022"},{"issue":"1","key":"12900_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02336-w","volume":"19","author":"HW Lai","year":"2021","unstructured":"Lai HW, Chang YL, Chen ST, et al. Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI. World J Surg Oncol. 2021;19(1):1\u201311. https:\/\/doi.org\/10.1186\/s12957-021-02336-w.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"12900_CR9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/jjco\/hyaa151","volume":"50","author":"Y Uemoto","year":"2020","unstructured":"Uemoto Y, Kondo N, Wanifuchi-Endo Y, et al. Sentinel lymph node biopsy may be unnecessary for ductal carcinoma in situ of the breast that is small and diagnosed by preoperative biopsy. Jpn J Clin Oncol. 2020;50(12):1364\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyaa151.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"12900_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.breast.2012.06.012","volume":"21","author":"J Kim","year":"2012","unstructured":"Kim J, Han W, Lee JW, et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 2012;21(5):641\u20135. https:\/\/doi.org\/10.1016\/j.breast.2012.06.012.","journal-title":"Breast"},{"issue":"1","key":"12900_CR11","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch TMG, Burger G, et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cellular Oncol. 2007;29(1):19\u201324.","journal-title":"Cellular Oncol"},{"issue":"6","key":"12900_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","volume":"74","author":"B van Calster","year":"2018","unstructured":"van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796\u2013804. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.038.","journal-title":"Eur Urol"},{"issue":"3","key":"12900_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-016-3783-2","volume":"156","author":"LM van Roozendaal","year":"2016","unstructured":"van Roozendaal LM, Goorts B, Klinkert M, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016;156(3):517\u201325. https:\/\/doi.org\/10.1007\/s10549-016-3783-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"12900_CR14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3892\/ol.2015.3480","volume":"10","author":"X Sun","year":"2015","unstructured":"Sun X, Li H, Liu YB, et al. Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences. Oncol Lett. 2015;10(3):1932\u20138. https:\/\/doi.org\/10.3892\/ol.2015.3480.","journal-title":"Oncol Lett"},{"issue":"2","key":"12900_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21535.Morbidity","volume":"102","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection Takamaru. J Surg Oncol. 2010;102(2):111\u20138. https:\/\/doi.org\/10.1002\/jso.21535.Morbidity.","journal-title":"J Surg Oncol"},{"issue":"6","key":"12900_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-018-0871-7","volume":"25","author":"Y Watanabe","year":"2018","unstructured":"Watanabe Y, Anan K, Saimura M, et al. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. Breast Cancer. 2018;25(6):663\u201370. https:\/\/doi.org\/10.1007\/s12282-018-0871-7.","journal-title":"Breast Cancer"},{"issue":"6","key":"12900_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1245\/s10434-018-6410-0","volume":"25","author":"BK Killelea","year":"2018","unstructured":"Killelea BK, Long JB, Dang W, et al. Associations between sentinel lymph node biopsy and complications for patients with ductal carcinoma in situ. Ann Surg Oncol. 2018;25(6):1521\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6410-0.","journal-title":"Ann Surg Oncol"},{"key":"12900_CR18","unstructured":"The National Comprehensive Cancer Network (NCCN). Breast Cancer. version 4. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419. Published 2022. Accessed August 12, 2022."},{"key":"12900_CR19","unstructured":"Nationaal Borstkanker Overleg Nederland (NABON). Dutch Breast Cancer Guideline, DCIS. https:\/\/www.oncoline.nl\/richtlijn\/item\/pagina.php?id=41192&richtlijn_id=1069. Published 2017. Accessed December 10, 2018."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12900-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T10:05:02Z","timestamp":1679306702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12900-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["12900"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12900-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"15 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Datasets were used, and the use of these datasets was approved by the scientific committee of PALGA (14.025 LZV1073 and LZV 2019-57) and the Privacy Review Board of IKNL (K14.021 and K19.199). The research was not subject to the Dutch Medical Research Involving Human Subjects Act (WMO).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}